

Positive News Coverage of EDAP's Ablatherm-HIFU treatment: "Man beats prostate cancer thanks to annual screening"

Below is the link to a recent news story that appeared on WRAL.com on 09/17/10 that highlights the benefits of EDAP's HIFU based on the experience of a patient treated in the Company's ENLIGHT clinical trial by Dr. Cary Robertson, a surgeon and urologist at Duke University, Durham NC, USA, and ENLIGHT Coordinating Principal Investigator. The article mentioned that the patient's "cancer is gone, thanks to an annual screening and early detection." The patient commented on his favorable experience in the trial by saying, "I have had very, very few side-effects to it."

This patient testimony corroborates growing interest for minimally invasive focused therapies as more and more patients opt for regular and early screening of their prostate. Ablatherm-HIFU, being the less invasive approach, is perfectly matching current trends and treatment strategies aiming at treating the increasing population of patients that are diagnosed at early stage of the disease and that want effective treatment with maximum preservation of their quality of life.

Please click the link below to access the news story and corresponding video that appears the web site for WRAL-TV, a CBS affiliate for Raleigh, Durham, Chapel Hill and Fayetteville.
<http://www.wral.com/lifestyles/healthteam/story/8309000/>

Ablatherm-HIFU (High Intensity Focused Ultrasound) is currently undergoing evaluation in a multicenter U.S. Phase II/III clinical trial under an Investigational Device Exemption granted by the FDA, the ENLIGHT U.S. clinical study.